McCoy's 5A Medium

McCoy's 5A medium

McCoy's 5A Medium

McCoy's 5A medium

From: 66 USD
Catalog #
(Select a product)
McCoy's 5A medium
Add to Wish List

Overview

McCoy's 5A Medium is recommended for a wide variety of cell culture applications. Selection of suitable nutrient medium is dependent on type of cell, conditions of culture, and degree of chemical definition required for the cell culture application.
Contains
• L-Glutamine
• Sodium bicarbonate
Subtype
Basal Media
Cell Type
Other
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Cell Culture

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
McCoy's 5A Medium
Catalog #
36350
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
McCoy's 5A Medium
Catalog #
36350
Lot #
All
Language
English

Resources and Publications

Publications (1)

Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. Thomas AM et al. Journal of controlled release : official journal of the Controlled Release Society 2011 MAR

Abstract

5-Fluorouracil (5-FU) is a small, very membrane permeable drug that is poorly retained within the aqueous compartment of liposomal nanoparticles (LNP). To address this problem a novel method relying on formation of a ternary complex comprising copper, low molecular weight polyethylenimine (PEI) and 5-FU has been developed. More specifically, in the presence of entrapped copper and PEI, externally added 5-FU can be efficiently encapsulated (textgreater95%) in DSPC/Chol (1,2-Distearoyl-sn-Glycero-3-Phosphocholine/cholesterol; 55:45 mol%) liposomes (130-170 nm) to achieve drug-to-lipid ratios of 0.1 (mol:mol). Drug release studies completed using this LNP formulation of 5-FU demonstrated significant improvements in drug retention in vitro and in vivo. Plasma concentrations of 5-FU were 7- to 23-fold higher when the drug was administered intravenously to mice as the LNP 5-FU formulation compared to free 5-FU. Further, the therapeutic effects of the LNP 5-FU formulation, as determined in a HT-29 subcutaneous colorectal cancer model where treatment was given QDx5, was greater than that which could be achieved with free 5-FU when compared at equivalent doses. This is the first time an active loading method has been described for 5-FU. The use of ternary metal complexation strategy to encapsulate therapeutic agents may define a unique platform for preparation of LNP drug formulations.